Picture loading failed.

Anti-CSF2 therapeutic antibody (Pre-made Gimsilumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Gimsilumab is a monoclonal antibody against granulocyte macrophage-colony stimulating factor (GM-CSF), which is a myeloid cell growth factor and pro- inflammatory cytokine. ... Inhibition of GM-CSF may be able to reverse this pathology.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-244-1mg 1mg 3090
GMP-Bios-ab-244-10mg 10mg 21890
GMP-Bios-ab-244-100mg 100mg 148000
GMP-Bios-ab-244-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CSF2 therapeutic antibody (Pre-made Gimsilumab biosimilar,Whole mAb)
INN Name Gimsilumab
TargetCSF2
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesLudwig Institute for Cancer Research;Morphotek
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedCancer;Rheumatoid arthritis
Development TechMORPHODOMA Technology